Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin glargine in metformin-treated adults with type 2 diabetes mellitus
ISRCTN87762302Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Exenatide arm with Insulin glargine arm (2 arms). Primary endpoint: Glycaemic control and beta-cell function. Started Oct 2004; status: completed.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN87762302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87762302.